Elevated MAP17 levels have been associated with good response to platinum-based compounds in cervical and laryngeal carcinomas [10, 11] and with increased sensitivity to bortezomib (Velcade, PS-341), a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma [12, 13] as well as breast tumours and sarcomas [7, 14, 15]. This evidence concerns the gene PDZK1IP1 and mantle cell lymphoma.